On March 15, OrbiMed Advisors increased its stake in RAPT Therapeutics by 556,273 shares during the fourth quarter. RAPT Therapeutics was acquired for $58 per share. Prior to the acquisition, OrbiMed's stake in the company was valued at approximately $56 million.
Nikesh Arora, the CEO of Palo Alto Networks, has purchased approximately $10 million worth of company stock, marking his first share purchase since November 2019. This insider move, coupled with a 'buy' recommendation from Trivariate Research, aims to bolster investor confidence following recent stock volatility.…
Read the full storyAnaptysBio (ANAB) has announced a strategic restructuring plan to spin off its biopharma operations into a new entity, First Tracks Biotherapeutics (TRAX). The spin-off is expected to be completed by April 20, 2026, with the new company launching with a robust cash balance of $180 million. Alongside the restructuring,…
Icahn Enterprises LP has significantly expanded its position in Centuri Holdings (CTRI) by purchasing approximately 3.49 million additional shares. The transaction is estimated to be worth around $77.99 million, based on the average quarterly share price. By the end of the quarter, the total value of the firm's…
Tarsus Pharmaceuticals (TARS) shares surged by 20% recently, demonstrating strong market momentum despite reports of insider selling. A company executive sold 12,274 shares in a transaction valued at approximately $839,000. The sale was executed at a weighted average price of $68.36 per share. According to regulatory…
OrbiMed Advisors significantly increased its position in RAPT Therapeutics during the fourth quarter, according to recent financial reports. The healthcare-focused investment firm added 556,273 shares to its holdings just before the company was acquired. RAPT Therapeutics was subsequently acquired at a price of $58…